Bio Path Holdings Inc
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. Its drug delivery and antisense technology is the DNAbilize, a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction by the body's enzymes when circulating in … Read more
Bio Path Holdings Inc (BPTH) - Total Assets
Latest total assets as of September 2025: $690.00K USD
Based on the latest financial reports, Bio Path Holdings Inc (BPTH) holds total assets worth $690.00K USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Bio Path Holdings Inc - Total Assets Trend (2003–2024)
This chart illustrates how Bio Path Holdings Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Bio Path Holdings Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Bio Path Holdings Inc's total assets of $690.00K consist of 97.2% current assets and 2.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 30.2% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2003–2024)
This chart illustrates how Bio Path Holdings Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Bio Path Holdings Inc's current assets represent 97.2% of total assets in 2024, an increase from 32.8% in 2003.
- Cash Position: Cash and equivalents constituted 30.2% of total assets in 2024, up from 7.9% in 2003.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2003.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Bio Path Holdings Inc Competitors by Total Assets
Key competitors of Bio Path Holdings Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Bio Path Holdings Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Bio Path Holdings Inc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Bio Path Holdings Inc is currently not profitable relative to its asset base.
Bio Path Holdings Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.08 | 0.86 | 13.65 |
| Quick Ratio | 0.08 | 0.86 | 13.65 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-8.02 Million | $ -476.00K | $ 14.79 Million |
Bio Path Holdings Inc - Advanced Valuation Insights
This section examines the relationship between Bio Path Holdings Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.90 |
| Latest Market Cap to Assets Ratio | 0.17 |
| Asset Growth Rate (YoY) | 20.6% |
| Total Assets | $3.88 Million |
| Market Capitalization | $642.33K USD |
Valuation Analysis
Below Book Valuation: The market values Bio Path Holdings Inc's assets below their book value (0.17 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Bio Path Holdings Inc's assets grew by 20.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Bio Path Holdings Inc (2003–2024)
The table below shows the annual total assets of Bio Path Holdings Inc from 2003 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $3.88 Million | +20.59% |
| 2023-12-31 | $3.22 Million | -79.84% |
| 2022-12-31 | $15.97 Million | -39.89% |
| 2021-12-31 | $26.57 Million | +61.26% |
| 2020-12-31 | $16.48 Million | -27.29% |
| 2019-12-31 | $22.66 Million | +870.45% |
| 2018-12-31 | $2.33 Million | -73.64% |
| 2017-12-31 | $8.86 Million | -27.37% |
| 2016-12-31 | $12.20 Million | +13.40% |
| 2015-12-31 | $10.76 Million | -30.51% |
| 2014-12-31 | $15.48 Million | +204.75% |
| 2013-12-31 | $5.08 Million | +116.70% |
| 2012-12-31 | $2.34 Million | -27.46% |
| 2011-12-31 | $3.23 Million | +3.94% |
| 2010-12-31 | $3.11 Million | -15.57% |
| 2009-12-31 | $3.68 Million | -16.08% |
| 2008-12-31 | $4.39 Million | +8829.45% |
| 2007-12-31 | $49.13K | -62.63% |
| 2006-12-31 | $131.49K | -7.52% |
| 2005-12-31 | $142.19K | 0.00% |
| 2004-12-31 | $142.19K | -5.29% |
| 2003-12-31 | $150.13K | -- |